With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Src family protein kinases (SFKs) play a key role in cell adhesion, invasion, proliferation,
survival, apoptosis, and angiogenesis during tumor development. In humans, SFKs consists …

Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to≥ 2
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …

Asciminib, the first BCR:: ABL1 inhibitor that S pecifically T argets the A BL M yristoyl P ocket
(STAMP), is approved worldwide for the treatment of adults with Philadelphia chromosome …

Abstract In PACE (Ponatinib Ph+ ALL and CML Evaluation), a phase 2 trial of ponatinib that
included patients with chronic-phase chronic myeloid leukemia (CP-CML) resistant to …

This analysis from the multicenter, open-label, phase 3 BFORE trial reports efficacy and
safety of bosutinib in patients with newly diagnosed chronic phase (CP) chronic myeloid …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
resulting from a reciprocal translocation between chromosomes 9 and 22 [t9; 22] that gives …

Asciminib is approved for patients with Philadelphia chromosome–positive chronic-phase
chronic myeloid leukemia (CML-CP) who received≥ 2 prior tyrosine kinase inhibitors or …

Many signaling pathways are dysregulated in cancer cells and the host tumor
microenvironment. Aberrant receptor tyrosine kinase (RTK) pathways promote cancer …

The development of BCR:: ABL1-targeting tyrosine kinase inhibitors (TKIs) has improved the
prognosis of patients with chronic myeloid leukemia (CML). Although there are some …